According to ACR pointers, allopurinol is strongly proposed as a primary-line urate-decreasing medication. Genetic tests is recommended (to get a variant identified as HLA B*5801) ahead of starting allopurinol because the carriers of the gene are at an elevated hazard of the significant allergic rea